Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
22.60
-0.16 (-0.70%)
Jun 2, 2026, 3:00 PM CST
SHA:605177 Revenue
Zhejiang East Asia Pharmaceutical had revenue of 264.57M CNY in the quarter ending March 31, 2026, with 38.58% growth. This brings the company's revenue in the last twelve months to 1.01B, down -2.19% year-over-year. In the year 2025, Zhejiang East Asia Pharmaceutical had annual revenue of 940.19M, down -21.54%.
Revenue (ttm)
1.01B
Revenue Growth
-2.19%
P/S Ratio
2.51
Revenue / Employee
669.64K
Employees
1,514
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 940.19M | -258.05M | -21.54% |
| Dec 31, 2024 | 1.20B | -158.21M | -11.66% |
| Dec 31, 2023 | 1.36B | 176.89M | 15.00% |
| Dec 31, 2022 | 1.18B | 467.34M | 65.62% |
| Dec 31, 2021 | 712.22M | -169.45M | -19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Kawin Technology Share-Holding | 1.30B |
| Shanghai Universal Biotech | 1.13B |
| Shandong Sito Bio-technology | 954.76M |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |
| Shanghai Model Organisms Center | 432.55M |
| Cabio Biotech (Wuhan) | 418.18M |
| Suzhou Fushilai Pharmaceutical | 412.51M |
| Yantai Zhenghai Biotechnology | 347.75M |